Company intelligence / Profile preview
Sapience Therapeutics, Inc.
Tarrytown, New York, United Statessapiencetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Two lead programs in Phase 2 clinical trials. ST316 showed signals of anti-tumor activity, strong pharmacodynamic data, and a clean safety profile in Phase 1. Lucicebtide (ST101) has shown efficacy proof-of-concept in patients with refractory solid tumors.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Peptide therapeutics (SPEARs™)SPARCs™
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Columbia UniversityUniversity of Bath
Beyond the preview
Go deeper on Sapience Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sapience Therapeutics, Inc..